PDF herunterladen
CC BY-NC-ND 4.0 · Ibnosina Journal of Medicine and Biomedical Sciences 2020; 12(03): 215-219
DOI: 10.4103/ijmbs.ijmbs_80_20
Case Report

Early-onset antibiotic-induced autoimmune hemolytic anemia

Mahmoud Kiblawi
1   Department of Internal Medicine, Sheikh Shakhbout Medical City, Abu Dhabi
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Drug-induced immune hemolytic anemia (DIIHA) is a rare adverse reaction that causes secondary autoimmune hemolytic anemia in susceptible patients. Drug-induced antibodies and nonimmunological protein absorption are the known mechanisms associated with DIIHA. The two most common reported antibiotics to cause drug dependent antibodies are cephalosporin and penicillin. The author reports two rare cases of DIIHA. The first case is a middle-aged woman clinically diagnosed with community-acquired pneumonia, which develops hemolytic anemia secondary to ceftriaxone. The second case is an elderly gentleman who developed DIIHA secondary to piperacillin–tazobactam that started managing gastrostomy site infection. Both patients had hypoxemia and shortness of breath secondary to drop in hemoglobin, but the outcome was uneventful. Antibiotic-induced hemolytic anemia can develop as early as 2 days after starting the antibiotic. Therefore, early diagnosis and discontinuation of the offending agent can prevent poor prognosis.

Key-words:

Autoimmune hemolytic anemia - ceftriaxone - direct antiglobulin test - hemolytic anemia - piperacillin–tazobactam

Financial support and sponsorship

Nil.




Publikationsverlauf

Eingereicht: 27. Juni 2020

Angenommen: 14. Juli 2020

Artikel online veröffentlicht:
14. Juli 2022

© 2020. The Libyan Authority of Scientific Research and Technologyand the Libyan Biotechnology Research Center. All rights reserved. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License,permitting copying and reproductionso long as the original work is given appropriate credit. Contents may not be used for commercial purposes, oradapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias. Haematologica 2014;99:1547-54.
  • 2 Chang A, Shruti Chaturvedi S, McCrae KR. Thirteen year retrospective analysis of adult patients with autoimmune hemolytic anemia at the Cleveland clinic: Diagnosis and prevalence of associated disorders. Blood 2013;122:955.
  • 3 Garratty G. Immune hemolytic anemia associated with drug therapy. Blood Rev 2010;24:143-50.
  • 4 Garratty G. Drug-induced immune hemolytic anemia. Hematology Am Soc Hematol Educ Program 2009;2009:73-9.
  • 5 Barcellini W. Immune hemolysis: Diagnosis and treatment recommendations. Semin Hematol 2015;52:304-12.
  • 6 Sartori A, Staley B, Skipper A. Drug-induced autoimmune hemolytic anemia in a 78-year-old African-American man with chronic lymphocytic leukemia. Lab Med 2014;45:105-8.
  • 7 Guleria VS, Sharma N, Amitabh S, Nair V. Ceftriaxone-induced hemolysis. Indian J Pharmacol 2013;45:530-1.
  • 8 Sarkar RS, Philip J, Mallhi RS, Jain N. Drug-induced immune hemolytic anemia (Direct Antiglobulin Test positive). Med J Armed Forces India 2013;69:190-2.
  • 9 Garbe E, Andersohn F, Bronder E, Klimpel A, Thomae M, Schrezenmeier H, et al. Drug induced immune haemolytic anaemia in the Berlin Case-Control Surveillance Study. Br J Haematol 2011;154:644-53.
  • 10 Leicht HB, Weinig E, Mayer B, Viebahn J, Geier A, Rau M. Ceftriaxone-induced hemolytic anemia with severe renal failure: A case report and review of literature. BMC Pharmacol Toxicol 2018;19:67.
  • 11 Leger RM, Arndt PA, Garratty G. How we investigate drug-induced immune hemolytic anemia. Immunohematology 2014;30:85-94.
  • 12 Garratty G. Drug-induced immune hemolytic anemia. Clin Adv Hematol Oncol 2010;8:98-101.